Deep Science Ventures

What Deep Science Ventures does

Deep Science Ventures (DSV) is a London-based venture creator founded in 2016 that builds deeptech companies by combining available scientific knowledge with founder-type scientists across five sectors: Agriculture, Climate, Computation, Pharma, and Education. Its core platform is the Outcomes Graph, a collaborative hyperlinked knowledge base that characterises outcomes, constraints, and solutions using dynamic logical operators, enabling the firm to work backwards from desired societal outcomes rather than forwards from existing ideas. DSV executes an 8-step venture creation methodology from sector identification through pre-incorporation de-risking to spin-out, and operates the Venture Science Doctorate, a sector-agnostic PhD programme providing 14 venture scientists access to 40+ global academic and industry lab partners.

The firm has launched 58 portfolio companies spanning direct air capture (Yama, Parallel Carbon), green hydrogen (Supercritical), critical metals extraction (Thunderstone), electrolytic iron/nickel (Ironic Metals), accelerated computing (Xonai), antibody discovery (Antiverse), cancer therapeutics (Enedra Therapeutics, Kindling Bio, CureAge Therapeutics), automated cell manufacturing (Mytos), and surgical optimisation (Scalpel). Portfolio-company funding has exceeded $240M from investors including Breakthrough Energy Ventures, Lowercarbon Capital, Sequoia, Sam Altman, and Patrick Collison, with portfolio valuation of $700M+. DSV operates offices in London, Tokyo, and Boston, and maintains funded corporate and philanthropic partnerships with AbbVie, Cancer Research UK, GSK, Anglo American, Coca-Cola, ARIA, Parkinson's UK, the Children's Tumor Foundation, the Cystic Fibrosis Foundation, CGIAR, SPRIND, Renaissance Philanthropy, and others.

DSV generates returns primarily through equity stakes retained when portfolio companies spin out, supplemented by funded partnership arrangements with corporate and philanthropic sponsors. The company does not sell products or services in the conventional sense; revenue derives from venture equity economics and partnership-funded programme management rather than disclosed pricing or product sales. Customer relationships are tripartite (founders, corporate partners, investors) and the firm does not publicly disclose revenue, pricing, or detailed financial terms.

Name

Deep Science Ventures

Legal name

Deep Science Ventures Limited

Website

https://deepscienceventures.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Deep Science Ventures is a London-based venture creator that builds deeptech companies across Agriculture, Climate, Computation, Pharma, and Education using an 8-step methodology anchored by its proprietary Outcomes Graph knowledge base and the Venture Science Doctorate programme.

Ownership category

akta.pro rank

Product category

Venture Creation Services

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417), Computer Systems Design Services (541512)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Computer Integrated Systems Design (7373), Services-Computer Programming Services (7371)

akta.pro industry

PRIMARYFSANAHAL

Corporate Deep Tech / R&D Commercialization CVC

Financial & Insurance/Private Equity & Venture Capital/Corporate Venture Capital (CVC)

SECONDARYFSANAHAE

Joint Venture CVC / Consortium Funds (Multi-corporate)

Financial & Insurance/Private Equity & Venture Capital/Corporate Venture Capital (CVC)

SECONDARYHLAAACAA

AAV Vector Gene Therapy Developers

Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

SECONDARYBPADALAB

Climate Finance, Carbon Markets & MRV Systems

Business & Public Services/International Organizations & Development/Climate, Environment & Sustainable Development Programs

Keywords

• Venture creation services
• Deep tech ventures
• Science venture building
• Venture science doctorate
• Outcomes graph platform

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Equity stakes in portfolio companies: DSV invests alongside other industry-leading investors when portfolio companies spin out from DSV. The company creates ventures and retains equity, generating returns through exits of portfolio companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

DSV is a venture creator that combines available scientific knowledge with founder-type scientists to build high-impact deeptech ventures across Agriculture, Computation, Climate, Pharma, and Education. It applies a proprietary 8-step venture creation methodology anchored by the Outcomes Graph knowledge base to scope sectors, identify founders, de-risk opportunities pre-incorporation, and spin out companies. DSV also runs the Venture Science Doctorate programme and maintains a global network of 40+ academic and industrial laboratory partners to support venture creation.

Product overview

Deep Science Ventures (DSV) is a venture creator that builds deeptech companies in four sectors: Agriculture, Climate, Computation, and Pharmaceuticals. Rather than a single software product, DSV operates through a venture creation methodology anchored by the Outcomes Graph—a proprietary knowledge coordination system—and the Venture Science Doctorate—an entrepreneurship-focused PhD programme. Their portfolio includes 58 launched companies across sectors including regenerative agriculture ventures (Rhizocore, PES, Hot Green Solutions), climate ventures (Yama, Parallel Carbon, Supercritical, Ironic Metals, Thunderstone, Mark1, Malachite), pharma ventures (Enedra Therapeutics, Kindling Bio, Neobe Therapeutics, CureAge Therapeutics, Antiverse, Mytos, Deliver Biosciences), and computation ventures (Dunia, Flow Engineering, Xonai, ConcR, Scalpel). The company supports these ventures through a global network of 40+ academic lab partners and has raised $240M+ from investors including Breakthrough Energy Ventures, Lowercarbon Capital, and Sequoia.

Differentiator

Problem solved

Functional benefit

Products and services

• Venture Science Doctorate Sector-agnostic, venture-focused doctoral training programme that provides full autonomy to select research topics, access to 40+ global laboratories, and an all-expenses-paid package covering tuition, stipends, travel, and research consumables. Aimed at founder-type scientists building deeptech ventures during their doctoral studies.
• Venture Creation Services End-to-end venture creation service in which DSV identifies sectors via the Outcomes Graph, scopes opportunities, recruits founder-scientists, applies first-principles analysis, builds teams, de-risks riskiest assumptions pre-incorporation, and spins out companies with investment from DSV and co-investors. Targeted at industry partners, founders and investors.
• Global Lab Network A decentralised network of 40+ leading academic and industrial laboratory partners across the UK, EU and US, including The National Physical Laboratory, GlaxoSmithKline, King's College London, Max Planck Institutes, The Helmholtz Association, EMBL, German Cancer Research Center, CGIAR, and others, providing venture scientists with fluid access to facilities across multiple countries.

Named customers17 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature2 records

Partnerships

19 partnerships are on record, tiered core and minor.

• Medicines Discovery CatapultcoreStrategic or Co-development Partner · 1 June 2026Collaboration to address challenge of delivering medicines across the blood-brain barrier into the central nervous system. First phase involves review of current medicines landscape to identify systemic gaps in brain-entry technologies. Long-term aim to spin out novel approaches into new ventures with pre-seed funding.
• Renaissance PhilanthropycoreStrategic or Co-development Partner · 1 March 2026Launched venture creation initiative under Climate Emergencies Resilience Lab (CERL) to develop field-ready crop resilience technologies. Addresses funding gap where traditional VC cannot support long-cycle, complex R&D required for climate solutions. Partners estimate climate-driven agricultural collapse could cost $1.8 trillion and 887 million years of healthy life by 2050.
• Future Fit AsiaminorGTM or Marketing Partner · 1 January 2026DSV partners with Future Fit Asia (formerly Future Food Asia) to deliver Grantham Foundation Detox Awards providing $90,000 in non-dilutive funding for solutions addressing chemical toxicity in human and natural systems.
• Global Impact CoalitionminorStrategic or Co-development Partner · 1 December 2024Leading platform enabling sustainability in the chemical sector partnered with DSV to accelerate sustainable innovation by uniting chemical industry expertise with DSV's venture creation model.
• General InceptionminorStrategic or Co-development Partner · 1 December 2024Partnership combines DSV's first-principles methodology and AI tools with General Inception's expertise in advancing early-stage innovations to drive scientific discovery and venture creation in fibrosis-focused therapeutics.
• RMI and Third DerivativeminorStrategic or Co-development Partner · 1 September 2024Joint launch of Mark1 to revolutionise project development for critical, capital-intensive climate tech startups. Addresses decarbonizing industrial heat in India and Southeast Asia where rapid urbanization drives demand for low-carbon heating solutions.
• The National Physical LaboratorycoreTechnology or Integration · 1 June 2024UK's national measurement laboratory partnered with DSV's Venture Science Doctorate programme, providing access to high-precision measurement facilities for venture scientists.
• GlaxoSmithKlinecoreTechnology or Integration · 1 June 2024Pharmaceutical partner in Venture Science Doctorate lab network, providing access to industry research facilities and expertise.
• King's College LondoncoreTechnology or Integration · 1 June 2024Academic partner in Venture Science Doctorate network, providing world-class research facilities including access to real patient samples for clinical research.
• Max Planck InstitutescoreTechnology or Integration · 1 June 2024German research network partner in Venture Science Doctorate programme, providing access to world-class German research facilities.
• The Helmholtz AssociationcoreTechnology or Integration · 1 June 2024Europe's largest research asset partnered with Venture Science Doctorate, providing access to extensive German research infrastructure.
• Health & Life Science Alliance Heidelberg MannheimcoreTechnology or Integration · 1 June 2024Includes European Molecular Biology Laboratory (EMBL) and German Cancer Research Center (DKFZ), providing comprehensive life science research facilities.
• CGIAR (Alliance of Bioversity International and CIAT)coreStrategic or Co-development Partner · 1 March 2024Partnership extends research, supervision and talent attraction capabilities of DSV's Venture Science Doctorate programme in agricultural sciences.
• Parkinson's UKminorStrategic or Co-development Partner · 1 December 2023Alliance to forge new pathways in Parkinson's therapeutics, applying DSV's venture creation approach to neurological disease treatment.
• Children's Tumor FoundationminorStrategic or Co-development Partner · 1 December 2022Partnership to uncover approaches within Neurofibromatosis, using DSV's methodology to identify novel therapeutic opportunities.
• Cystic Fibrosis FoundationminorStrategic or Co-development Partner · 1 December 2022Partnership to uncover approaches within Cystic Fibrosis using DSV's venture creation methodology to identify novel therapeutic opportunities.
• AbbViecoreStrategic or Co-development Partner · 1 November 2022Global pharmaceutical partnership to create ventures targeting immune-mediated inflammatory diseases using DSV's venture creation methodology.
• Cancer Research UKcoreStrategic or Co-development Partner · 1 August 2022Expanded partnership to develop curative therapies for cancer patients. DSV uses venture creation methodology to uncover novel therapeutics approaches in oncology.
• CRUSA FoundationminorStrategic or Co-development Partner · 1 August 2022Costa Rican foundation partnered with DSV for Tropical Agriculture & Bioeconomy Initiative, creating companies focused on regenerative agriculture in Costa Rica.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Entrepreneur First: Global venture builder that identifies and recruits technical founders (often scientists) to build deep tech companies from inception, retaining equity. EF operates the same founder-finding, first-principles venture studio model as DSV across multiple geographies, making it the closest head-to-head peer.
• Flagship Pioneering: US-based venture creator that originates and builds biotech and life sciences companies from scratch, retaining significant equity through a defined creation methodology. Comparable to DSV's Pharma sector in process and economics, and the most successful example of a science-first venture studio.
• Antler: Global venture builder that recruits founders in cohorts and supports them through company creation, with significant portfolio breadth across geographies. Antler's founder-finding, cohort-based model parallels DSV's Venture Science Doctorate and sector-led venture creation approach.
• SOSV: Multi-stage venture firm operating vertical accelerators (HAX for hardware, IndieBio for biotech, dlab for computational biology) that creates and invests early in deep tech startups. Overlaps directly with DSV's portfolio verticals — particularly biotech, hardware/climate, and computation.
• Creative Destruction Lab: Science-based venture builder with objective-driven cohorts that help founders translate research into high-impact companies. CDL's methodology of working from scientific objectives to commercial outcomes mirrors DSV's Outcomes Graph approach.
• Betaworks: New York-based venture studio that builds and invests in early-stage technology companies from inception. While less deep-tech focused than DSV, Betaworks shares the studio-style venture creation and equity retention model with comparable portfolio economics.

Emerging players

• Science Creates Ventures: UK-based deep tech VC that co-invested with DSV in Houdini Bio's pre-Seed. Operates in the same UK deep tech ecosystem with similar sector overlap (biotech, climate) and represents an adjacent funding partner / partial peer in venture creation territory.

Regional players

• Stride.VC: UK-based early-stage venture capital firm that partners with founders at company creation. Shares DSV's UK base and founder-led investing ethos but with a more generalist portfolio rather than DSV's deep tech sector specialism.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/deepsciventures
• LinkedInlinkedin.com/company/deep-science-ventures

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments20 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Deep Science Ventures